Cost Analysis of Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia at King Chulalongkorn Memorial Hospital
Sureerat Ngamkiatphaisan MSc*, Jiruth Sriratanaban MD, PhD**, Pirom Kamolratanakul MD, MSc***, Tanin Intragumtornchai MD, MSc***, Nopadon Noppakun MD**, Pongpisut Jongudomsuk MD****
Affiliation : * Health Insurance Coordinating Center, King Chulalongkorn Memorial Hospital, Bangkok ** Faculty of Medicine, Chulalongkorn University, Bangkok *** Faculty of Medicine, Chulalongkorn University, Bangkok **** Bureau of Policy and Planning, National Health Security Office, Bangkok
The purpose of the study was to analyze the first-year cost of hematopoietic stem cell transplantation (HSCT) program for the treatment of adult patients with acute myeloid leukemia (AML) at King Chulalongkorn Memorial Hospital (KCMH). The present retrospective study was carried out on 67 AML patients treated with bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT) at KCMH during the period of 1994 to 2005. The actual total one-year cost from the provider perspective were determined by the reviewing medical records for medical care costs (MCCs) and by adjusting data from the reports of annual cost analysis of KCMH for routine services costs (RSCs). All costs were converted to 2006 values using the Thai consumer price indices. It was found that the full cost of allogeneic HSCT (allo-HSCT) and autologous HSCT (auto-HSCT) in the first year of the program was $22,592.85 and $24,171.25 per case respectively. Cost-effective appraisal, comparing with chemotherapy, need to be studied further.
Keywords : Cost analysis, Hematopoietic stem cell transplantation, Acute myeloid leukemia
